Rethinking Premeds
Feb 27, 2025•9 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time!
Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158
Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470
We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.
For the best experience, listen in Metacast app for iOS or Android